OSLI Retina

June 2019

Issue link: http://osliretina.healio.com/i/1128895

Contents of this Issue

Navigation

Page 73 of 75

404 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® Follow OSLIJournal OSLI Retina SLACK Incorporated News and Notes SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson SALES Chief Commercial Officer Matthew J. Holland Group Sales Director, Eye Care Scott Wright National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Recruitment/Classified Sales Representative Bernadette Hamilton Sales Coordinator, Recruitment Jennifer Carroll Reprints/Eprints Licensing Opportunities: Sheridan Content Solutions scsreprints@sheridan.com DESIGN Creative Director Thomas Cavallaro Production and Circulation Director Cheryl McKeown Production Associate Ryan Davis The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker News and Notes FDA Partially Lifts Clinical Hold for Adverum's Wet AMD Gene Therapy The U.S. Food and Drug Administration has partially lifted the clinical hold on Adverum Biotechnologies' (Menlo Park, CA) wet age-related macular degenera- tion gene therapy treatment candidate, ADVM-022, allowing a phase 1 trial to continue, the company announced in a press release. The second cohort of the OPTIC trial will now receive a dose of 2 × 1011 vg per eye, which is three times lower than the first cohort's dose of 6 × 1011 vg per eye, rather than the 2 × 1012 vg per eye that the company originally had planned due to preliminary anatomical response observed in the first cohort. A planned third cohort, which would have received a dose of 6 × 1012 vg per eye, is still on partial clinical hold, and the company does not plan to dose at this level, the release said. "Given the encouraging robust anatomical response from patients in the first cohort, we will begin dosing patients in the second cohort at a lower dose of 2 × 1011 vg per eye, instead of dose escalating as previously planned," Adverum CEO Leone Patterson said in the release. Originally posted on www.Healio.com on May 21, 2019. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2019. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $222, electronic only: $197. Institutional: One year—$692. Residents and fellows: $111 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $71 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $99. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - June 2019